Gallbladder Disease from GLP-1 Medications in New Jersey
Last Updated: April 1, 2026
Gallbladder Disease cases linked to GLP-1 medications are being filed by New Jersey residents. New Jersey is one of the most critical states for pharmaceutical litigation in the United States, as it is home to the headquarters of numerous major pharmaceutical companies and has a well-developed body of drug liability law. The state's 9.3 million residents and two-year statute of limitations, combined with a robust discovery rule, create a dynamic legal landscape for Depo-Provera and GLP-1 claims. New Jersey's courts have extensive experience handling complex pharmaceutical cases, including multi-county mass tort programs.
Gallbladder Disease has been linked to GLP-1 medications including Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, Trulicity. New Jersey residents who developed gallbladder disease after using these drugs may qualify for compensation. The product liability statute of limitations in New Jersey is 2 years. Cases are pending in federal MDL, and attorneys handle claims on a contingency fee basis — no cost unless you win.
Gallbladder Disease and GLP-1 Medications
Gallbladder disease encompassing gallstones, cholecystitis (gallbladder inflammation), and other biliary complications has been linked to GLP-1 medications including Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, Trulicity. New Jersey residents who developed gallbladder problems after starting these medications may have experienced severe right-sided abdominal pain, particularly after eating, along with nausea, fever, and jaundice. Many patients ultimately require cholecystectomy — the surgical removal of the gallbladder. Even after surgery, some patients experience ongoing digestive complications known as postcholecystectomy syndrome.
The manufacturers of these medications — Novo Nordisk (maker of Ozempic, Wegovy, and Rybelsus) and Eli Lilly (maker of Mounjaro and Trulicity) — are accused of failing to adequately warn patients and prescribing physicians about the risk of gallbladder disease. Despite internal data and emerging clinical evidence suggesting a causal link, the drug labels did not include sufficient warnings about the severity and potential permanence of this condition.
For New Jersey residents, this means that if you developed gallbladder disease while taking a GLP-1 medication, you may have a valid product liability claim. The federal multidistrict litigation (MDL 3094) is consolidating these cases for efficient pretrial proceedings, while preserving each plaintiff's individual right to trial.
Recognizing Gallbladder Disease from GLP-1 Drugs
If you are a New Jersey resident who used Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, or Trulicity and experienced any of the following symptoms, you may have developed gallbladder disease as a result:
Severe pain in upper right abdomen
Pain after eating fatty foods
Nausea and vomiting
Fever and chills
Jaundice
Diagnosis
Gallbladder Disease is typically confirmed through ultrasound, hida scan, or ct imaging. If you are experiencing symptoms but have not yet received a formal diagnosis, an attorney can help coordinate appropriate medical evaluation as part of your case. Having documented medical evidence strengthens your claim significantly.
Filing a Gallbladder Disease Claim in New Jersey
New Jersey residents who developed gallbladder disease after using GLP-1 medications have specific legal options and deadlines. The statute of limitations for product liability claims in New Jersey is 2 years, and the personal injury statute of limitations is 2 years.
Importantly, New Jersey recognizes the discovery rule. This means the statute of limitations clock may not start until you knew or reasonably should have known that your gallbladder disease was caused by a GLP-1 medication. Given that the scientific understanding of the link between these drugs and gallbladder disease has evolved significantly in recent years, many New Jersey residents may still be within their filing window even if their injury occurred some time ago.
Cases may be filed in the New Jersey Superior Courts at the state level or in federal court through the District of New Jersey. Most GLP-1 injury cases are being coordinated through the federal MDL for pretrial proceedings.
New Jersey legal landscape: New Jersey applies modified comparative fault with a 50% bar and follows the New Jersey Products Liability Act (N.J.S.A. 2A:58C). The state provides a rebuttable presumption that an FDA-approved drug is not defective, but plaintiffs can overcome this by showing the manufacturer withheld or misrepresented information to the FDA. Residents in Newark, Jersey City, Paterson, Elizabeth, and Edison and surrounding areas should consult with an attorney to evaluate their potential gallbladder disease claim.
Personal Injury SOL
2 years
Product Liability SOL
2 years
Discovery Rule
Yes
GLP-1 Drugs Linked to Gallbladder Disease
The following GLP-1 receptor agonist medications have been linked to gallbladder disease in ongoing litigation. If you used any of these drugs in New Jersey and developed gallbladder disease, you may qualify for a claim:
Ozempic
Semaglutide injection by Novo Nordisk. Prescribed for type 2 diabetes.
Wegovy
Semaglutide injection by Novo Nordisk. Prescribed for weight management.
Mounjaro
Tirzepatide injection by Eli Lilly. Prescribed for type 2 diabetes and weight management.
Rybelsus
Oral semaglutide by Novo Nordisk. Prescribed for type 2 diabetes.
Saxenda
Liraglutide injection by Novo Nordisk. Prescribed for weight management.
Trulicity
Dulaglutide injection by Eli Lilly. Prescribed for type 2 diabetes.
Do You Qualify for a Gallbladder Disease Claim in New Jersey?
New Jersey residents may be eligible to file a gallbladder disease claim if the following criteria apply:
Used a GLP-1 Medication
You were prescribed and used Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, or Trulicity or another GLP-1 receptor agonist medication.
Diagnosed with Gallbladder Disease
You received a medical diagnosis of gallbladder disease through ultrasound, hida scan, or ct imaging.
Injury Occurred After Drug Use
Your gallbladder disease developed after you began taking the GLP-1 medication, establishing a timeline consistent with causation.
Within New Jersey's Filing Deadline
Your claim falls within New Jersey's product liability statute of limitations (2 years). The discovery rule may extend this deadline. An attorney can evaluate your specific timeline.
Gallbladder Disease in New Jersey: FAQ
What is gallbladder disease and how is it linked to GLP-1 medications in New Jersey?
Gallstones, cholecystitis, or other gallbladder complications requiring surgery. GLP-1 medications including Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, Trulicity have been linked to an increased risk of developing this condition. New Jersey residents who were prescribed these medications and subsequently developed gallbladder disease may be eligible to file a lawsuit seeking compensation for their injuries, medical expenses, and other damages.
What are the symptoms of gallbladder disease caused by Ozempic or other GLP-1 drugs?
Common symptoms of gallbladder disease include severe pain in upper right abdomen, pain after eating fatty foods, nausea and vomiting, fever and chills, jaundice. If you experienced these symptoms after taking Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, or Trulicity in New Jersey, you should seek medical attention immediately and consider having your case evaluated for potential legal action.
How is gallbladder disease diagnosed for purposes of a GLP-1 lawsuit?
Gallbladder Disease is typically diagnosed through ultrasound, hida scan, or ct imaging. For New Jersey residents filing a GLP-1 injury claim, medical documentation confirming your diagnosis is important for establishing your case. If you have not yet been formally diagnosed but are experiencing symptoms, your attorney can help coordinate appropriate medical evaluation.
What is the statute of limitations for a gallbladder disease claim in New Jersey?
In New Jersey, the statute of limitations for product liability claims is 2 years. New Jersey recognizes the discovery rule, meaning the filing deadline may start from when you discovered or should have discovered that your gallbladder disease was caused by a GLP-1 medication. Consult with an attorney to determine your exact deadline.
What compensation can I receive for gallbladder disease caused by GLP-1 drugs in New Jersey?
New Jersey residents who qualify may recover compensation for medical expenses (including cholecystectomy surgery, hospitalization, and follow-up care), lost wages, pain and suffering, emotional distress, and diminished quality of life. The amount depends on the severity of your gallbladder disease and its impact on your daily life.
Is there any cost to file a gallbladder disease claim in New Jersey?
There is no upfront cost. Attorneys handling GLP-1 gallbladder disease cases in New Jersey work on a contingency fee basis, meaning they only receive payment if you receive compensation through settlement or trial verdict. NuLegal's initial case review is completely free with no obligation.
Other GLP-1 Injuries in New Jersey
New Jersey Residents: Get Your Free Case Review
If you developed gallbladder disease after using Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, or Trulicity, time may be limited. New Jersey's product liability statute of limitations is 2 years. Get a free, no-obligation evaluation today.
Free Case ReviewAdvertisement
Disclosure: NuLegal operates as a legal referral service. Attorney Ashkaan Hassan evaluates claims and refers qualified cases to specialized trial firms, earning a referral fee from the attorney's share of any recovery. Clients never pay out of pocket.